BioCentriq and panCELLa in Agreement to Study Stem Cell-derived Natural Killer Cell Expansion Technology
New Jersey-based CDMO, BioCentriq, has entered into a research agreement with panCELLa, a Pluristyx company, to evaluate the effectiveness of panCELLa’s genetically-engineered, induced pluripotent stem cell-derived feeder cells in expanding natural killer (NK) cells.
“We envision the panCELLa-provided feeder line as an effective tool in our quest to accelerate the manufacturing of NK cell therapies and can be added to BioCentriq’s proprietary LEAP™ platform,” commented Alex Klarer, Vice President of Business Strategy and Innovation at BioCentriq.
“Our LEAP-NK™ platform is specifically designed to help biotech companies with promising NK cell therapies advance from lab to clinic in half the time it would normally take by leveraging proven technology, completed development work and established processes ready for GMP production.”
The panCELLa feeder line is a stable and scalable platform that can be fine-tuned to enhance NK cell activation, expansion, and manufacturability. BioCentriq will expand and cryopreserve the feeder cell bank as a reagent to activate adult and iPSC-derived NK cells and evaluate viable cell yield and potency in static and dynamic culture conditions.
The partnership aims to accelerate the manufacturing of NK cell therapies and reduce the time needed for GMP production from lab to clinic. A research version of panCELLa’s feeder line is available for evaluation and a clinical-grade format for therapeutic use through panCELLa and its sub-licensees.
How are you enjoying this news article? Let us know your thoughts, here >>
BioCentriq will add the technology to its proprietary LEAP platform designed to help biotech companies with promising NK cell therapies advance from lab to clinic in half the time.
“We are pleased that BioCentriq selected our feeder line technology to better serve their cell therapy clients in solving the challenges of NK cell commercial manufacturing. We look forward to working with BioCentriq to bring the next generation of customized cell products and service solutions to speed the transition of these revolutionary therapies from the benchtop to the bedside,” concluded Mahendra Rao, Chief Scientific Officer at Pluristyx.
Source: BioCentriq Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to firstname.lastname@example.org.